Science Portal
v2.1.5127.produseast1
Copyright © Médecins Sans Frontières
v2.1.5127.produseast1
The endTB project aims to find shorter, less toxic and more effective treatments for ‘multidrug-resistant TB’ (MDR-TB) through:
Covering 18 countries, the project is a partnership between Partners In Health, Médecins Sans Frontières, Interactive Research & Development and financial partners Unitaid and the Transformational Investment Capacity (TIC) of MSF. This collection contains the final and intermediate results of the studies, advocacy reports, and study presentations. For more information about the endTB project, visit https://endtb.org/.
BACKGROUND
For decades, poor treatment options and low-quality evidence plagued care for patients with rifampin-resistant tuberculosis. The advent of new drugs ...
BACKGROUND
Aft...
RATIONALE
Treatment outcomes may be compromised among patients with multidrug- or rifampicin-resistant tuberculosis with additional fluoroquinolone resis...
endTB Observational Study had sites in 17 countries. In each country, sites enrolled patients on treatment with bedaquiline and delamanid according to National TB Program guidelines, ...
This document is designed to give guidance to the endTB Project sites on the response to the COVID-19 outbreak. It is intended to be a resource for physicians and other health care pr...
Tuberculosis (TB) is the world’s deadliest infectious disease, and drug-resistant (DR) TB is a global health emergency. The World Health Organization (WHO) has estimated that only 1 i...
Delamanid should be effective against highly resistant strains of Mycobacteriumtuberculosis, but uptake has been slow globally. In the endTB (expand new drug markets for TB) Observati...
Drug resistance is a major public health crisis thwarting the effective treatment and care of people living with tuberculosis (TB) – the world’s leading infectious disease killer. Dec...
Researchers from endTB participated in the WHO Global Consortium to share updated results and the study’s implementation practices, in addition to evidence to support the transition, ...
Pharmacovigilance forms and other resources for staff on endTB sites.
Although tuberculosis (TB) is the number-one infectious disease killer and one of the top ten causes of mortality worldwide, the global response to TB remains off track. 2 The interim...
Out of Step 2017 includes the results of a 29-country survey on national TB policies and practices. The report was created to identify gaps in implementation and monitor progress towa...
The endTB Medical Committee formulates recommendations for off-label and compassionate use of the new anti-TB drugs for M(X)DR-TB.
It provides advice to any MSF, PIH and IRD pro...
This guide is designed to give guidance to the endTB Project site on the use of new TB drugs bedaquiline and delamanid. It is intended to be a resource for physicians and other health...
This 20-page guide is designed to provide all endTB stakeholders with a detailed presentation of the project's four goals.
This report – now in its fourth edition – analyses the barriers and factors affecting access to treatment regimens for drug-resistant tuberculosis (DR-TB), including new and repurpose...